Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma
NCT05281926Phase 1Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Oct 2021
- Primary completion
- Jun 2024
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of poly iclc in hepatocellular carcinoma (HCC), sponsored by National Taiwan University Hospital. Primary endpoint: Area Under the Concentration-Time Curve (0-22 weeks). Status: unknown.
02
Drugs
poly iclc
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05281926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05281926.